The extrinsic ocular muscles in birds are derived from the prechordal plate

Franz Wachtler,H. J. Jacob,M. Jacob,B. Christ

DOI: https://doi.org/10.1007/BF00410750

1984-07-01

Die Naturwissenschaften

Abstract:

What problem does this paper attempt to address?

The phenotypic characteristic observed by cardiac magnetic resonance in a PLN-R14del family

Xincheng Jiang,Yuanwei Xu,Jiayu Sun,Lili Wang,Xinli Guo,Yucheng Chen

DOI: https://doi.org/10.1038/s41598-020-73359-8

IF: 4.6

2020-10-05

Scientific Reports

Abstract:Abstract Phospholamban (PLN) is an important regulator for sarcoendoplasmic reticulum (SR) calcium transport ATPase (SERCA), which uptakes Ca 2+ to SR during the diastolic phase of cardiomyocytes to maintain intracellular calcium homeostasis. Mutations on PLN result in intracellular calcium disorder, myocardial contraction defect, and eventually heart failure and/or malignant ventricular arrhythmia. Since 2003, several kinds of PLN mutations have been identified in familial dilated cardiomyopathy (DCM) patients, illustrating a few clinical characteristics that differs from classical DCM patients. Herein, we report a large PLN-R14del family with typical clinical characteristics reported including relatively late-onset clinical symptoms, low-voltage in ECG, as well as frequent ventricular arrythmias. Moreover, members underwent cardiac magnetic resonance (CMR) examination showed a strikingly similar pattern of late gadolinium enhancement (LGE)—Sub-epicardial involvement in the left ventricular (LV) lateral wall with or without linear mid-wall enhancement in the interventricular septum. The former one can also present in younger PLN-R14del carriers despite completely normal LV structure and function. Meanwhile, T1 mapping also found significantly increased extracellular volume (ECV) in PLN-R14del carriers. These findings highlight the special role of CMR to phenotyping PLN-induced cardiomyopathy patients and distinguish them from other types of cardiomyopathy.

multidisciplinary sciences
Association Between SCN5A R225Q Variant and Dilated Cardiomyopathy: Potential Role of Intracellular Ph and WNT/β-catenin Pathway

Jingjing Hu,Kun Yang,Yongchao Zhao,Zilun Wei,Lebing Yang,Rifeng Gao,Yonghui Wu,Lei Xu,Sujuan Xu,Kai Hu,Aijun Sun,Junbo Ge

DOI: https://doi.org/10.1136/jmedgenet-2021-108396

2022-01-01

Journal of Medical Genetics

Abstract:BackgroundThe SCN5A variant is a common cause of familial dilated cardiomyopathy (DCM). We previously reported a SCN5A variant (c.674G>A), located in the high-risk S4 segment of domain I (DI-S4) region in patients with idiopathic DCM and R225Q knockin (p.R225Q) mice carrying the c.674G>A variant exhibited prolonged baseline PR intervals without DCM phenotypes. In this study, we explored the association and mechanism between R225Q variant and DCM phenotype.MethodsPrevalence of DI-S4 variant was compared between patients with idiopathic DCM and the control participants. R225Q knockin and wild-type (WT) mice were subjected to doxorubicin (DOX), D-galactose (D-gal) or D-gal combined with DOX.ResultsClinical data suggested that the prevalence of DI-S4 variant was higher in DCM group than in the control group (4/90 (4.4%) vs 3/1339 (0.2%), p<0.001). Cardiomyocytes from R225Q knockin mice treated with D-gal and DOX exhibited more significant hypertrophic phenotype and weaker contraction/dilation function and an increased level of apoptosis as compared with WT mice. Mechanistically, we found that R225Q variant could increase intracellular pH and further induce the activation of the WNT/β-catenin pathway as well as the overexpression of pro-hypertrophic and pro-apoptotic targets. WNT-C59 inhibitor improved cardiac function in the R225Q knockin mice treated with D-gal and DOX.ConclusionOur results suggest that R225Q variant is associated with increased susceptibility to DCM. Ageing could enhance this process via activating WNT/β-catenin signaling in response to increased intracellular pH. Antagonising the WNT/β-catenin pathway might be a potential therapeutic strategy for mitigating R225Q variant-related DCM pathogenesis.
Next-generation Sequencing Identified Novel Desmoplakin Frame-Shift Variant in Patients with Arrhythmogenic Cardiomyopathy

Xiaoping Lin,Yuankun Ma,Zhejun Cai,Qiyuan Wang,Lihua Wang,Zhaoxia Huo,Dan Hu,Jian'an Wang,Meixiang Xiang

DOI: https://doi.org/10.1186/s12872-020-01369-5

2019-01-01

Abstract:BackgroundArrhythmogenic cardiomyopathy (AC) is one of the leading causes for sudden cardiac death (SCD). Recent studies have identified mutations in cardiac desmosomes as key players in the pathogenesis of AC. However, the specific etiology in individual families remains largely unknown.MethodsA 4-generation family presenting with syncope, lethal ventricular arrhythmia and SCD was recruited. Targeted next generation sequencing (NGS) was performed and validated by Sanger sequencing. Plasmids containing the mutation and wild type (WT) were constructed. Real-time PCR, western-blot and immunofluorescence were performed to detect the functional change due to the mutation.ResultsThe proband, a 56-year-old female, presented with recurrent palpitations and syncope. An ICD was implanted due to her family history of SCD/ aborted SCD. NGS revealed a novel heterozygous frame-shift variant (c.832delG) in Desmoplakin (DSP) among 5 family members. The variant led to frame-shift and premature termination, producing a truncated protein. Cardiac magnetic resonance (CMR) of the family members carrying the same variant shown myocardium thinning and fatty infiltration in the right ventricular, positive bi-ventricular late gadolinium enhancement and severe RV dysfunction, fulfilling the diagnostic criteria of AC. HEK293T cells transfected with mutant plasmids expressed truncated DSP mRNA and protein, upregulation of nuclear junction plakoglobin (JUP) and downregulation of beta-catenin, when compared with WT.ConclusionWe infer that the novel c.832delG variant in DSP was associated with AC in this family, likely through Wnt/beta-catenin signaling pathway.
Mutations of plakophilin-2 in Chinese with arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Xiaoliang Qiu,Wenling Liu,Dayi Hu,Tiangang Zhu,Cuilan Li,Lei Li,Chengjun Guo,Xingpeng Liu,Lei Wang,Hua Zheng,Chunling Wang,Qing Diao,Dan Shi,Pingyun Zhan,Yuanming Deng,Kunshen Liu,Yi Wang,Baomin Liu,Hongming Liu,Li Zhang

DOI: https://doi.org/10.1016/j.amjcard.2009.01.356

IF: 3.133

2009-01-01

The American Journal of Cardiology

Abstract:Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited heart muscle disease associated with increased risks of sudden death, particularly in young, otherwise healthy, patients. The pathologic features are progressive myocardial atrophy and fibrofatty replacement. Plakophilin-2 (PKP2) is reported as the most common ARVD/C-causing gene in Western countries. In this study we aimed to determine the prevalence of PKP2 mutations in Chinese patients with ARVD/C and their phenotype characteristics. Genotype and phenotype were investigated in a cohort of 18 unrelated Chinese patients with a clinical diagnosis of ARVD/C. Direct sequencing of PKP2 led to the identification of 5 novel heterozygous mutations (R158K, Q211X, L419S, A793D, and N852fsX930) in 39% of patients (7 of 18) with ARVD/C. Among them, N852fsX930 was found in 3 unrelated young patients who presented with symptomatic ventricular tachyarrhythmia. Nevertheless, no significant difference could be detected between patients with ARVD/C with (n = 7) and without (n = 11) PKP2 mutations with regard to the phenotype characteristics and clinical outcomes. Decreased penetrance was prominent in family members. In conclusion, 5 novel PKP2 mutations were identified in a cohort of symptomatic Chinese patients with ARVD/C. N852fsX930 appeared to be a hot-spot mutation in which patients presented with a severe ARVD/C phenotype, and 2/3 had early onset of arrhythmic events. No significant difference was found in phenotype characteristics between patients with ARVD/C with and without PKP2 mutations. The decreased penetrance indicated that an ARVD/C diagnosis cannot solely rely on genotyping results. (c) 2009 Elsevier Inc. All rights reserved. (Am J Cardiol 2009;103:1439-1444)
Impaired autophagy mechanisms associated with phospholamban-R14del disease

E Vafiadaki,E G Kranias,A G Eliopoulos,D Sanoudou

DOI: https://doi.org/10.1093/cvr/cvae088.106

IF: 13.081

2024-05-31

Cardiovascular Research

Abstract:Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): Leducq Foundation Phospholamban (PLN) is a key modulator of sarcoplasmic reticulum Ca2+ homeostasis and cardiac contractility. The PLN variant c.40_42delAGA (p.R14del) leads to arrhythmogenic cardiomyopathy characterized by life-threatening ventricular arrhythmias and sudden cardiac death. A large number of PLN-R14del carriers have been identified worldwide, although the expanding use of genetic testing and increased awareness is unveiling a higher frequency. PLN-containing aggregates are emerging as a hallmark of this disease, and are increasingly believed to be associated with disease pathogenesis. However, the mechanism leading to the formation of aggregates is unknown. We performed an in depth molecular and cellular analysis utilizing in vitro systems to determine if these aggregates result from aberrations in autophagy, and the underlying mechanisms. Utilizing cell culture systems we studied the expression level and subcellular distribution of fundamental autophagy-related proteins and evaluated the impact of autophagy inducers and inhibitors. Expression of PLN-R14del in different cell culture systems (HEK293 and H9c2 cells) was found to result in PLN aggregate formation, which were determined to contain the autophagy marker proteins sequestosome-1 (p62) and microtubule-associated protein light chain 3 (LC3), indicating inefficient degradation by the autophagy pathway. In support of this, PLN-R14del expressing cells were shown to exhibit increased p62 and LC3-II protein levels. This was associated with significantly reduced autophagic flux, as demonstrated by examination of LC3-II protein levels after autophagy inhibition. Moreover, by detailed immunofluorescence analysis, we determined reduced co-localization of the autophagosomal protein LC3 and the lysosomal associated membrane protein 1 (LAMP1) in PLN-R14del cells, suggesting impaired autophagosome-lysosome fusion. We next examined the distribution of key proteins mediating autophagosome-lysosome membrane fusion including the Ras-related protein Rab7, the ultraviolet radiation resistance-associated gene (UVRAG) and membrane tether proteins. In PLN-R14del transfected cells, significant alterations in their co-localization with LC3 were observed, indicating their impaired recruitment to the autophagosomes. Importantly, in PLN-WT cells changes in cytosolic Ca2+ levels by thapsigargin treatment were found to recapitulate the autophagic defects of PLN-R14del, suggesting that Ca2+ alterations are a contributing factor of PLN-R14del mediated aberrant autophagy. In conclusion, our findings reveal a causal relationship between PLN-R14del and autophagy dysregulation, through inhibition of autophagosome-lysosome fusion and autophagic flux reduction. This ultimately leads to aggregate formation, an early pathological sign in human patients.

cardiac & cardiovascular systems
Phosphoproteomics of PLN R14del heart tissue reveals major myocyte degenerate phenotype, and is attenuated by PLN antisense treatment in vitro

F E Deiman,P Davidsson,D Spater,A N Linders,I B Dias,K F Arevalo Gomez,A Esquivel-Gaytan,K Andrysiak,A Walentinsson,C Ahlstrom,A E Mullick,K M Hansson,N Bomer,N Grote Beverborg,P Van Der Meer

DOI: https://doi.org/10.1093/eurheartj/ehae666.3786

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background/Purpose: Phospholamban (PLN) p.Arg14del (R14del, R14Δ/+) is a pathogenic variant that can cause cardiomyopathy, characterized by PLN protein aggregation, ultimately leading to heart failure (HF). The exact pathophysiology is unknown, we aim to uncover R14Δ/+ disease mechanisms and study potential treatment using PLN antisense oligonucleotides (PLN-ASOs). Methods Phosphoproteomics was performed on human heart tissue from end-stage R14Δ/+ patients (N=6) versus other etiologies of HF (N=10) as a control. CRISPR-Cas9 engineered R14Δ/+ and isogenic control (WT) induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) were extensively characterized, including the phosphoproteome, calcium transients (FLUO 4-AM), mitochondrial respiration (Seahorse Mito Stress Test) and contractility in dynamic engineered heart tissues (dyn-EHTs) before and after PLN-ASO treatment, and the results were validated in R14Δ/+ iPSC-CMs derived from R14Δ/+ patients. Results Phosphoproteomics of heart tissue from R14Δ/+ vs. other etiologies of HF identified 138 differentially expressed proteins (DEPs) and 317 differentially expressed phosphoproteins (DEPPs), therewith establishing a disease-specific signature. Phosphoproteomics of WT vs. R14Δ/+ iPSC-CMs identified 451 DEPs and 1046 DEPPs. Gene ontology analysis of end-stage R14Δ/+ heart tissue and iPSC-CMs revealed a large overlap. Here, R14Δ/+ showed to have great impact on contraction (e.g. SYNPO2L, MYH10, TTN) and calcium (e.g. AHNAK, HRC, RYR2). In line with this, functional characterization revealed that R14Δ/+ iPSC-CMs have an increased Ca2+ systolic velocity and accelerated calcium transient (decreased T50 and T90), that associated with altered calcium-related DEPPs (e.g. RYR2). In dyn-EHTs, R14Δ/+ dyn-EHTs have a decreased contraction duration, time-to-peak and ability to pace, associated with altered contractility-related DEPPs (e.g. SYNPO2L, MYH7, TTN). PLN-ASOs dose-dependently altered PLN mRNA expression and protein levels in iPSC-CMs, and 62 DEPs and 372 DEPPs were identified. PLN-ASOs increased Ca2+ diastolic velocity, which associated with altered calcium-related DEPPs (e.g. PLN, AHNAK, HRC). PLN-ASOs increased the ability of dyn-EHTs to pace and therewith improved contractility, which associated with altered contractility-related DEPPs (e.g. SYNPO2L, MYH7, TTN). PLN-ASOs dose-dependently increased basal respiration and ATP production, which associated with altered mitophagy-related DEPs (GABARAPL2 and MAP1LC3). These functional characteristics were validated in R14Δ/+ patient iPSC-CMs. Discussion: R14Δ/+ cardiomyocytes have a degenerative phenotype characterized by altered calcium transients and reduced contractility and PLN-ASOs attenuate these characteristics and improve metabolism.

cardiac & cardiovascular systems
Phospholamban p.Leu39* Cardiomyopathy Compared with Other Sarcomeric Cardiomyopathies: Age-Matched Patient Cohorts and Literature Review

Andreea Sorina Afana,Laura Vasiliu,Radu Sascău,Robert Daniel Adam,Cristina Rădulescu,Sebastian Onciul,Eliza Cinteză,Adela Chirita-Emandi,Ruxandra Jurcuț

DOI: https://doi.org/10.3390/jcdd11020041

2024-01-28

Journal of Cardiovascular Development and Disease

Abstract:Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder, most often caused by sarcomeric gene mutations, with a small proportion due to variants in non-sarcomeric loci. Phospholamban (PLN) is a phosphoprotein associated with the cardiac sarcoplasmic reticulum, a major determinant of cardiac contractility and relaxation. We conducted a retrospective study to determine the prevalence, phenotypical spectrum and clinical course of patients carrying the PLN p.Leu39* variant. A cohort including 11 PLN patients was identified among all patients with HCM (9/189, 4.8%) and DCM (2/62, 3.2%) who underwent genetic testing from two tertiary centers and five more were detected through cascade screening. Complete phenotyping was performed. PLN p.Leu39* variant-driven cardiomyopathy presented mostly as hypertrophic, with frequent progression to end-stage dilated HCM. We proceeded to compare these results to a similar analysis of a control cohort consisting of age-matched individuals that inherited pathogenic or likely pathogenic variants in common sarcomeric genes (MYBPC3/MYH7). Overall, the clinical characteristics and examination findings of patients carrying PLN p.Leu39* were not different from patients with cardiomyopathy related to sarcomeric mutations except for the presence of pathological Q waves and the incidence of non-sustained ventricular arrhythmias, which were higher in PLN patients than in those with MYBPC3/MYH7-related diseases.

cardiac & cardiovascular systems
Association of PLXND1 with a novel subtype of anomalous pulmonary venous return

Wei-Zhen Zhou,Ziyi Zeng,Huayan Shen,Wen Chen,Tianjiao Li,Baihui Ma,Yang Sun,Fangfang Yang,Yujing Zhang,Wenke Li,Bianmei Han,Xuewen Liu,Meng Yuan,Guangxin Zhang,Yang Yang,Xiaoshuang Liu,Kun-Jing Pang,Shou-Jun Li,Zhou Zhou

DOI: https://doi.org/10.1093/hmg/ddab331

IF: 5.1214

2021-11-15

Human Molecular Genetics

Abstract:Abstract Anomalous pulmonary venous return (APVR) is a potentially lethal congenital heart disease. Elucidating the genetic etiology is crucial for understanding its pathogenesis and improving clinical practice, whereas its genetic basis remains largely unknown because of complex genetic etiology. We thus performed whole-exome sequencing for 144 APVR patients and 1636 healthy controls and report a comprehensive atlas of APVR-related rare genetic variants. Novel singleton, loss-of-function and deleterious missense variants (DVars) were enriched in patients, particularly for genes highly expressed in the developing human heart at the critical time point for pulmonary veins draining into the left atrium. Notably, PLXND1, encoding a receptor for semaphorins, represents a strong candidate gene of APVR (adjusted P = 1.1e-03, odds ratio: 10.9–69.3), accounting for 4.17% of APVR. We further validated this finding in an independent cohort consisting of 82 case–control pairs. In these two cohorts, eight DVars were identified in different patients, which convergently disrupt the GTPase-activating protein-related domain of PLXND1. All variant carriers displayed strikingly similar clinical features, in that all anomalous drainage of pulmonary vein(s) occurred on the right side and incorrectly connected to the right atrium, which may represent a novel subtype of APVR for molecular diagnosis. Studies in Plxnd1 knockout mice further revealed the effects of PLXND1 deficiency on severe heart and lung defects and cellular abnormalities related to APVR such as abnormal migration and vascular formation of vascular endothelial cells. These findings indicate the important role of PLXND1 in APVR pathogenesis, providing novel insights into the genetic etiology and molecular subtyping for APVR.

genetics & heredity,biochemistry & molecular biology
[Oxidation of elementary sulfur by Thiobacillus thiooxidans].

G. Karavaiko,T. Pivovarova

1973-05-01

Микробиология

Abstract:
Pathogenic cardiomyopathy gene variants inform prognosis in atrial fibrillation: results from exome sequencing in over 17,000 patients in TIMI trials

S Jurgens,G E M Melloni,S Kany,D D Berg,M P Bonaca,R P Giugliano,S D Wiviott,D L Bhatt,P G Steg,I Raz,J P Pirruccello,M S Sabatine,N A Marston,P T Ellinor,C T Ruff

DOI: https://doi.org/10.1093/eurheartj/ehae666.3665

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Rare genetic variants in cardiomyopathy genes are associated with risk of atrial fibrillation (AF), even in the absence of overt ventricular dysfunction. Data on clinical outcomes for rare genetic variant carriers among patients with AF remain sparse. Purpose We aimed to study the prognostic implication of rare pathogenic/likely pathogenic (PLP) variants for dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC) in patients with AF from large, well-phenotyped randomized clinical trials. Methods and results Rare variants were called using exome sequencing data in 5 large clinical trials from the TIMI study group (ENGAGE-AF, FOURIER, SAVOR, PEGASUS, DECLARE). PLP variants for cardiomyopathy were identified using phenotype- and gene-specific curation of protein-truncating variants and high-confidence variant classifications from the ClinVar database. In 17,190 patients with a history of AF, we identified 421 (2.4%) PLP variant carriers (age 67±10, 35% women) and 16,769 (97.6%) pts without PLP variants (age 70±9, 36% women). Among these individuals, we identified 265 DCM carriers (1.5%), 106 (0.6%) HCM carriers and 54 (0.3%) ARVC carriers. In this cohort, 9,275 (54%) had a history of heart failure (HF) and 2,991 (17.4%) prior ischemic stroke. Over 2.5 years median follow-up, 1,365 pts (7.9%) were hospitalized for HF, 599 (3.5%) had an ischemic stroke, and 1147 (6.7%) died of cardiovascular causes. In logistic regression analyses adjusting for age, sex, trial, and principal components of ancestry, PLP variants were significantly associated with a history of HF (OR 1.66, p<0.0001), most notably for DCM variants (OR 1.97, 1.48-2.62, p<0.0001). PLP variants were independently associated with incident HF admissions (adj HR 1.75, 1.39-2.29, p<0.0001), most notably for HCM (adj HR 2.59, 1.68-3.99, p<0.0001) and ARVC variants (adj HR 2.50, 1.34-4.66, p=0.004). The increased risk of HF admissions remained consistent in patients with (adj HR 1.49, 1.11-2.00, p=0.009) and those without (adj HR 1.88, 1.00-3.54, p=0.049) a history of HF. PLP variants were also associated with higher risk of cardiovascular death (adj HR 1.46, 1.06-2.02, p=0.02), most notably for DCM variants (adj HR 1.77, 1.21-2.58, p=0.003). In contrast, PLP variants were not associated with history of ischemic stroke at baseline (adj OR 0.99, p=0.96) nor with incident ischemic stroke (adj HR 0.95, p=0.84). Conclusion In patients with AF, rare cardiomyopathy gene variants are associated with increased risks of HF and of cardiovascular death, but not stroke. These results, collected from large well-phenotyped randomized clinical trials, demonstrate an important prognostic implication for rare genetic variants for CMP in pts with AF.

cardiac & cardiovascular systems
Early consequences of the phospholamban mutation PLN‐R14del+/− in a transgenic mouse model

Claudia Maniezzi,Marem Eskandr,Chiara Florindi,Mara Ferrandi,Paolo Barassi,Elena Sacco,Valentina Pasquale,Angela S. Maione,Giulio Pompilio,Vivian Oliveira Nunes Teixeira,Rudolf A. Boer,Herman H. W. Silljé,Francesco Lodola,Antonio Zaza,Rudolf A. de Boer

DOI: https://doi.org/10.1111/apha.14082

IF: 7.523

2024-01-14

Acta Physiologica

Abstract:Aims The heterozygous phospholamban (PLN) mutation R14del (PLN R14del+/−) is associated with a severe arrhythmogenic cardiomyopathy (ACM) developing in the adult. "Superinhibition" of SERCA2a by PLN R14del is widely assumed to underlie the pathogenesis, but alternative mechanisms such abnormal energy metabolism have also been reported. This work aims to (1) to evaluate Ca2+ dynamics and energy metabolism in a transgenic (TG) mouse model of the mutation prior to cardiomyopathy development; (2) to test whether they are causally connected. Methods Ca2+ dynamics, energy metabolism parameters, reporters of mitochondrial integrity, energy, and redox homeostasis were measured in ventricular myocytes of 8–12 weeks‐old, phenotypically silent, TG mice. Mutation effects were compared to pharmacological PLN antagonism and analyzed during modulation of sarcoplasmic reticulum (SR) and cytosolic Ca2+ compartments. Transcripts and proteins of relevant signaling pathways were evaluated. Results The mutation was characterized by hyperdynamic Ca2+ handling, compatible with a loss of SERCA2a inhibition by PLN. All components of energy metabolism were depressed; myocyte energy charge was preserved under quiescence but reduced during stimulation. Cytosolic Ca2+ buffering or SERCA2a blockade reduced O2 consumption with larger effect in the mutant. Signaling changes suggest cellular adaptation to perturbed Ca2+ dynamics and response to stress. Conclusions (1) PLN R14del+/− loses its ability to inhibit SERCA2a, which argues against SERCA2a superinhibition as a pathogenetic mechanism; (2) depressed energy metabolism, its enhanced dependency on Ca2+ and activation of signaling responses point to an early involvement of metabolic stress in the pathogenesis of this ACM model.

physiology
PHENOTYPE DIFFERENCE BETWEEN GENOTYPE OF PLAKOPHILIN-2 MUTATION AND DESMOGLEIN-2 MUTATION IN SYMPTOMATIC CHINESE PATIENTS WITH ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA/CARDIOMYOPATHY-A REPORT FROM CHINESE ARVD REGISTRY

Wen Liu,Wenling Liu,Xiaoliang Qiu,Dayi Hu,Tiangang Zhu,Cuilan Li,Lei Li

DOI: https://doi.org/10.1136/heartjnl-2012-302920a.255

IF: 5.7

2012-01-01

Heart

Abstract:Objectives Arrhythmogenic Right Ventricular Dysplasia/cardiomyopathy (ARVD/C) is an inherited heart muscle disease associated mainly with the mutations of desmosome. Plakophilin-2 (PKP2) and desmoglein-2 (DSG-2) are reported as the most two common ARVD-causing genes in western countries. In this study we aim to determine the prevalence of PKP2 and DSG2 mutations in Chinese ARVD/C patients, and their phenotype characteristics. Methods Genotype and phenotype were investigated in a cohort of 23 symptomatic unrelated Han Chinese with a clinical diagnosis of ARVD. PKP2 and DSG2 genes were identiﬁed using PCR and direct sequencing. Clinical evaluation included family and personal medical histories, 12-lead electrocardiography, transthoracic echocardiography, signal average electrocardiography, 24-h ambulatory electrocardiography, and MRI in some patients. Results Five novel heterozygous mutations (R158K, Q211X, L419S, A793D and N852fsX930) of PKP2 were identified in 30% (7/23) of ARVD patients; three mutations (R46G, D494A and F531C) in DSG2 were identified 13% (3/23) of the patients. Among the positive patients initial symptoms occurred at 30±10 years. All of them documented VT. Symptoms of the patients with PKP2 mutation were severe than that of patients with DSG2 mutation, all of the patients with PKP2 mutation had syncope, but none of the patients with DSG2, they only had palpitation. most of the patients with PKP2 mutation (6/7) showed epsilon waves in ECGs but only one in patients with DSG2; 6 patients with PKP2 mutation showed inverted T wave in V1 to V3, but only one in patients with DSG2 mutation. Conclusions Five novel heterozygous mutations (R158K, Q211X, L419S, A793D and N852fsX930) of PKP2 and three heterozygous mutations (R46G, D494A and F531C) of DSG2 were identified. The study has revealed a greater frequency of occurrence of PKP2 mutations when compared to DSG2 mutations. There are some difference between patients with PKP2 mutation and that with DSG2 mutation including clinical symptom and ECGs. It seems that phenotype of PKP2 mutation were severe than that of DSG2 mutation in this cohort.
Identification of a LMNA (c.646c > T) Variant by Whole-Exome Sequencing in Combination with a Dilated Cardiomyopathy (DCM) Related Gene Filter in a Family with Familiar DCM

Liang Chen,Zhou Zhongyin,Hang Lu,Yan Xie,Gang Li,Jianfei Huang,Zhao Dong-sheng

DOI: https://doi.org/10.7555/jbr.32.20180003

2018-01-01

Abstract:Dilated cardiomyopathy (DCM) is characterized by the dilated heart chambers and reduced systolic function in the absence of specific aetiology [1] .Approximately one third of DCM cases are hereditary.In recent years, DCM concomitant with arrhythmias and sudden death resulting from gene mutation has been widely reported [2] .In the current study, we report the identification of a mutation within lamin A (LMNA) (p.R216C) in a Han Chinese family with similar cardiac manifestations by using whole-exome sequencing in combination with a related gene filter and co-segregation analysis.The study was approved by the local Ethics Committee of the First People ' s Hospital of Nantong Jiangsu.A family from Jiangsu Province in eastern China was investigated with 24 hours-Holter monitoring and transthoracic echocardiography and the pedigree was built using Microsoft Office [3] .The information of the family members is shown in Fig. 1 and Table 1.Ⅲ4 (the proband, male, 53 years old) was hospitalized due to recurrent dizziness and amaurosis in 2012.The electrocardiogram showed grade 3 atrioventricular block (AVB), and a pacemaker was implanted.Both Ⅱ5 (male, 71 years old) and Ⅱ11 (male, 63 years old) had heart enlargement and pacemaker implantation for grade 3 AVB, and suffered from atrial fibrillation (2
Genotype-phenotype relationship in patients with arrhythmogenic right ventricular cardiomyopathy caused by desmosomal gene mutations: A systematic review and meta-analysis

Zhenyan Xu,Wengen Zhu,Cen Wang,Lin Huang,Qiongqiong Zhou,Jinzhu Hu,Xiaoshu Cheng,Kui Hong

DOI: https://doi.org/10.1038/srep41387

IF: 4.6

2017-01-25

Scientific Reports

Abstract:The relationship between clinical phenotypes and desmosomal gene mutations in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) is poorly characterized. Therefore, we performed a meta-analysis to explore the genotype-phenotype relationship in patients with ARVC. Any studies reporting this genotype-phenotype relationship were included. In total, 11 studies involving 1,113 patients were included. The presence of desmosomal gene mutations was associated with a younger onset age of ARVC (32.7 ± 15.2 versus 43.2 ± 13.3 years; P = 0.001), a higher incidence of T wave inversion in V1–3 leads (78.5% versus 51.6%; P = 0.0002) or a family history of ARVC (39.5% versus 27.1%; P = 0.03). There was no difference in the proportion of males between desmosomal-positive and desmosomal-negative patients (68.3% versus 68.9%; P = 0.60). The presence of desmosomal gene mutations was not associated with global or regional structural and functional alterations (63.5% versus 60.5%; P = 0.37), epsilon wave (29.4% versus 26.2%; P = 0.51) or ventricular tachycardia of left bundle-branch morphology (62.6% versus 57.2%; P = 0.30). Overall, patients with desmosomal gene mutations are characterized by an earlier onset age, a higher incidence of T wave inversion in V1–3 leads and a strong family history of ARVC.

multidisciplinary sciences
The Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy

Dries A.M. Feyen,Isaac Perea-Gil,Renee G.C. Maas,Magdalena Harakalova,Alexandra A. Gavidia,Jennifer Arthur Ataam,Ting-Hsuan Wu,Aryan Vink,Jiayi Pei,Nirmal Vadgama,Albert J. Suurmeijer,Wouter P. te Rijdt,Michelle Vu,Prashila L. Amatya,Maricela Prado,Yuan Zhang,Logan Dunkenberger,Joost P.G. Sluijter,Karim Sallam,Folkert W. Asselbergs,Mark Mercola,Ioannis Karakikes

DOI: https://doi.org/10.1161/circulationaha.120.049844

IF: 37.8

2021-05-02

Circulation

Abstract:Background: Phospholamban (PLN) is a critical regulator of calcium cycling and contractility in the heart. The loss of arginine at position 14 in PLN (R14del) is associated with dilated cardiomyopathy (DCM) with a high prevalence of ventricular arrhythmias. How the R14 deletion causes DCM is poorly understood and there are no disease-specific therapies. Methods: We used single-cell RNA sequencing to uncover PLN R14del disease-mechanisms in human induced pluripotent stem cells (hiPSC-CMs). We utilized both 2D and 3D functional contractility assays to evaluate the impact of modulating disease relevant pathways in PLN R14del hiPSC-CMs. Results: Modeling of the PLN R14del cardiomyopathy with isogenic pairs of hiPSC-CMs recapitulated the contractile deficit associated with the disease in vitro . Single-cell RNA sequencing revealed the induction of the unfolded protein response pathway (UPR) in PLN R14del compared to isogenic control hiPSC-CMs. The activation of UPR was also evident in the hearts from PLN R14del patients. Silencing of each of the three main UPR signaling branches (IRE1, ATF6, or PERK) by siRNA exacerbated the contractile dysfunction of PLN R14del hiPSC-CMs. We explored the therapeutic potential of activating the UPR with a small molecule activator, BiP protein Inducer X (BiX). PLN R14del hiPSC-CMs treated with BiX showed a dose-dependent amelioration of the contractility deficit of in both 2D cultures and 3D engineered heart tissues without affecting calcium homeostasis. Conclusions: Together, these findings suggest that the UPR exerts a protective effect in the setting of PLN R14del cardiomyopathy and that modulation of the UPR might be exploited therapeutically.

cardiac & cardiovascular systems,peripheral vascular disease
[The Clinical Analysis of Plakophilin-2 Gene Mutation in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy/dysplasia].

Xin Liu,Wenling Liu,Dayi Hu,Li Zhang,Tiangang Zhu,Cuilan Li,Xiaoliang Qiu,Lei Li,Chengjun Guo,Xingpeng Liu,Lei Wang,Hua Zheng,Chunling Wang,Qing Diao,Dan Shi,Pingyun Zhan,Yuanming Deng,Kunshen Liu,Yi Wang,Baomin Liu,Hongming Liu,Xuguang Qin,Yanping Lan

2015-01-01

Abstract:OBJECTIVE:The purpose of this study was to screen genetic variations in plakophilin-2 (PKP2) gene in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) and investigate the differences in clinical features between mutation and no-mutation groups.METHODS:Thirty unrelated Chinese patients clinically diagnosed with ARVC/D and 50 healthy controls were included. Genomic DNA was isolated from peripheral blood samples. PCR and direct sequencing were used to detect variations in PKP2 gene.RESULTS:Eight PKP2 mutant variants were identified in 10 ARVC/D patients (8 men, 2 women). Among the eight mutation, three (c.2194C>T, c. 1170+ 1G>A and c. 810_813delGGTC) were novel mutation. Clinical features of the PKP2 mutation group were similar to those of the non-mutation group.CONCLUSIONS:The rate of PKP2 mutation is 33.3% (10/30) in ARVC/D patients. The penetrance of PKP2 mutation for ARVC/D tends to be higher in man patients. No significant differences could be detected in phenotype characteristics between patients with and without PKP2 mutation.
Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation

Friederike Cuello,Anika E Knaust,Umber Saleem,Malte Loos,Janice Raabe,Diogo Mosqueira,Sandra Laufer,Michaela Schweizer,Petra Kraak,Frederik Flenner,Bärbel M Ulmer,Ingke Braren,Xiaoke Yin,Konstantinos Theofilatos,Jorge Ruiz‐Orera,Giannino Patone,Birgit Klampe,Thomas Schulze,Angelika Piasecki,Yigal Pinto,Aryan Vink,Norbert Hübner,Sian Harding,Manuel Mayr,Chris Denning,Thomas Eschenhagen,Arne Hansen

DOI: https://doi.org/10.15252/emmm.202013074

2021-05-16

EMBO Molecular Medicine

Abstract:The phospholamban (PLN) p.Arg14del mutation causes dilated cardiomyopathy, with the molecular disease mechanisms incompletely understood. Patient dermal fibroblasts were reprogrammed to hiPSC, isogenic controls were established by CRISPR/Cas9, and cardiomyocytes were differentiated. Mutant cardiomyocytes revealed significantly prolonged Ca2+ transient decay time, Ca2+‐load dependent irregular beating pattern, and lower force. Proteomic analysis revealed less endoplasmic reticulum (ER) and ribosomal and mitochondrial proteins. Electron microscopy showed dilation of the ER and large lipid droplets in close association with mitochondria. Follow‐up experiments confirmed impairment of the ER/mitochondria compartment. PLN p.Arg14del end‐stage heart failure samples revealed perinuclear aggregates positive for ER marker proteins and oxidative stress in comparison with ischemic heart failure and non‐failing donor heart samples. Transduction of PLN p.Arg14del EHTs with the Ca2+‐binding proteins GCaMP6f or parvalbumin improved the disease phenotype. This study identified impairment of the ER/mitochondria compartment without SR dysfunction as a novel disease mechanism underlying PLN p.Arg14del cardiomyopathy. The pathology was improved by Ca2+‐scavenging, suggesting impaired local Ca2+ cycling as an important disease culprit.

medicine, research & experimental
When Paying Attention Pays Back: Missense Mutation c.1006G>A p. (Val336Ile) in PRKAG2 Gene Causing Left Ventricular Hypertrophy and Conduction Abnormalities in a Caucasian Patient: Case Report and Literature Review

Emanuele Micaglio,Lara Tondi,Sara Benedetti,Maria Alessandra Schiavo,Antonia Camporeale,Giandomenico Disabato,Andrea Attanasio,Gianluigi Guida,Gianpaolo Carrafiello,Massimo Piepoli,Pietro Spagnolo,Carlo Pappone,Massimo Lombardi

DOI: https://doi.org/10.3390/ijms25179171

2024-08-23

Abstract:PRKAG2 cardiomyopathy is a rare genetic disorder that manifests early in life with an autosomal dominant inheritance pattern. It harbors left ventricular hypertrophy (LVH), ventricular pre-excitation and progressively worsening conduction system defects. Its estimated prevalence among patients with LVH ranges from 0.23 to about 1%, but it is likely an underdiagnosed condition. We report the association of the PRKAG2 missense variant c.1006G>A p. (Val336Ile) with LVH, conduction abnormalities (short PR interval and incomplete right bundle branch bock) and early-onset arterial hypertension (AH) in a 44-year-old Caucasian patient. While cardiac magnetic resonance (CMR) showed a mild hypertrophic phenotype with maximal wall thickness of 17 mm in absence of tissue alterations, the electric phenotype was relevant including brady-tachy syndrome and recurrent syncope. The same variant has been detected in the patient's sister and daughter, with LVH + early-onset AH and electrocardiographic (ECG) alterations + lipothymic episodes, respectively. Paying close attention to the coexistence of LVH and ECG alterations in the proband has been helpful in directing genetic tests to exclude primary cardiomyopathy. Hence, identifying the genetic basis in the patient allowed for familial screening as well as a proper follow-up and therapeutic management of the affected members. A review of the PRKAG2 cardiomyopathy literature is provided alongside the case report.
P5-108

Wenling Liu,Jielin Pu,Dayi Hu VI,Cuilan Li,Yuanming Deng,Pingyu Zhan,Dan Shi,Baoming Liu,Guoqing Gu,Quanxing Lu,Xianli Yang,Guangping Li,Liuan Zhuo,Xiaofeng He,Li Zhang

DOI: https://doi.org/10.1016/j.hrthm.2006.02.886

IF: 6.779

2006-01-01

Heart Rhythm

Abstract:Arrhythmogenic right ventricular dysplasia (ARVD) is a cardiomyopathy (C) featured by frequent ventricular tachycardia (VT), heart failure and sudden death (SD). ARVD is mostly caused by mutations of genes encoding desmosome proteins, which result in cell-cell communication dysfunction, progressive myocardial atrophy and fibrofatty replacement predominantly in the right ventricle (RV). Since most ARVD cases were reported in Caucasians, this study aimed to summarize the clinical presentations in Chinese.
LV-predominant arrhythmogenic cardiomyopathy related to pathogenic DSP-variant

Soban Ahmad,Husam El Sharu,Robin Fernandes,Mark Kolasa,Constantin Bogdan Marcu

DOI: https://doi.org/10.1002/ccr3.9003

2024-05-31

Abstract:Key clinical message: In contrast to previously thought, arrhythmogenic cardiomyopathy can occur exclusively in the left ventricle in association with autosomal dominant mutation, even without any skin manifestations. Abstract: We present a case of a 43-year-old male with left ventricle (LV)-predominant arrhythmogenic cardiomyopathy (ACM) caused by a novel p.Q1830 mutation in the desmoplakin (DSP) gene. The patient had a significant family history of sudden cardiac death (SCD) and presented with presyncope and exertional dyspnea. The patient's electrocardiography (ECG) showed frequent premature ventricular complexes (PVCs) with bigeminy and couplet patterns. Cardiac magnetic resonance imaging (CMR) revealed late gadolinium enhancement of the left ventricle (LV) and ventricular systolic dysfunction, suggesting LV-predominant arrhythmogenic cardiomyopathy. The patient was started on guideline-directed medical therapy (GDMT), and an implantable cardioverter-defibrillator (ICD) was implanted for primary prevention. The patient reported significant improvement in his heart failure symptoms at the 2-year follow-up. The article highlights the importance of timely diagnosis with multimodality imaging and genetic testing and management of the rare DSP-related LV-predominant ACM associated with a high risk of SCD.

The extrinsic ocular muscles in birds are derived from the prechordal plate

The phenotypic characteristic observed by cardiac magnetic resonance in a PLN-R14del family

Association Between SCN5A R225Q Variant and Dilated Cardiomyopathy: Potential Role of Intracellular Ph and WNT/β-catenin Pathway

Next-generation Sequencing Identified Novel Desmoplakin Frame-Shift Variant in Patients with Arrhythmogenic Cardiomyopathy

Mutations of plakophilin-2 in Chinese with arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Impaired autophagy mechanisms associated with phospholamban-R14del disease

Phosphoproteomics of PLN R14del heart tissue reveals major myocyte degenerate phenotype, and is attenuated by PLN antisense treatment in vitro

Phospholamban p.Leu39* Cardiomyopathy Compared with Other Sarcomeric Cardiomyopathies: Age-Matched Patient Cohorts and Literature Review

Association of PLXND1 with a novel subtype of anomalous pulmonary venous return

[Oxidation of elementary sulfur by Thiobacillus thiooxidans].

Pathogenic cardiomyopathy gene variants inform prognosis in atrial fibrillation: results from exome sequencing in over 17,000 patients in TIMI trials

Early consequences of the phospholamban mutation PLN‐R14del+/− in a transgenic mouse model

PHENOTYPE DIFFERENCE BETWEEN GENOTYPE OF PLAKOPHILIN-2 MUTATION AND DESMOGLEIN-2 MUTATION IN SYMPTOMATIC CHINESE PATIENTS WITH ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA/CARDIOMYOPATHY-A REPORT FROM CHINESE ARVD REGISTRY

Identification of a LMNA (c.646c &gt; T) Variant by Whole-Exome Sequencing in Combination with a Dilated Cardiomyopathy (DCM) Related Gene Filter in a Family with Familiar DCM

Genotype-phenotype relationship in patients with arrhythmogenic right ventricular cardiomyopathy caused by desmosomal gene mutations: A systematic review and meta-analysis

The Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy

[The Clinical Analysis of Plakophilin-2 Gene Mutation in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy/dysplasia].

Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation

When Paying Attention Pays Back: Missense Mutation c.1006G>A p. (Val336Ile) in PRKAG2 Gene Causing Left Ventricular Hypertrophy and Conduction Abnormalities in a Caucasian Patient: Case Report and Literature Review

P5-108

LV-predominant arrhythmogenic cardiomyopathy related to pathogenic DSP-variant

Identification of a LMNA (c.646c > T) Variant by Whole-Exome Sequencing in Combination with a Dilated Cardiomyopathy (DCM) Related Gene Filter in a Family with Familiar DCM